About Xcell Therapeutics
Xcell Therapeutics is a publicly listed company based in Seoul (South Korea) founded in 2015. Serum-free media for MSC cell culture is developed and provided. It operates in the Healthcare and Technology sectors. The company has 68 employees. Its chief executive, as recorded, is Uri Uiil Lee. Xcell Therapeutics offers products and services including CellCorâ„¢ and Exosome Isolation Device. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Cell Culture. Its legal entity is Xcell Therapeutics Inc.
Company details
Xcell Therapeutics was founded in 2015 in Seoul, South Korea, within the biotechnology sector focused on regenerative medicine. Proprietary serum-free media, such as CellCor SFD MSCa fully defined optionand CellCor CD MSCa chemically defined variantare produced for cell culture applications. These products support pharmaceutical solutions in regenerative therapies, with operations centered on advancing cell-based treatments.
- Headquarters Seoul, South Korea
- Employees 68
- Stage Public
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website xcell.co.kr
- Legal Name Xcell Therapeutics, Inc.
- Annual Revenue$1.35 M (USD)0.76as on Dec 31, 2025
- Net Profit-$7.57 M (USD)-14.5as on Dec 31, 2025
- EBITDA-$6.34 M (USD)-19.15as on Dec 31, 2025
- Employee Count68
Products & Services of Xcell Therapeutics
Xcell Therapeutics offers a comprehensive portfolio of products and services, including CellCor™ and Exosome Isolation Device.
Serum-free media for optimal cell culture in regenerative therapies
Device for isolating exosomes in research and medical applications
People of Xcell Therapeutics
1 people are tracked at Xcell Therapeutics (1 in leadership); the tracked headcount is 68.
| Name | Role | Group |
|---|---|---|
Uri Uiil Lee | CEO | Leadership |
Complete people profiles for Xcell Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Xcell Therapeutics
Xcell Therapeutics is a publicly listed company on the KRX with ticker symbol 373110 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Jul 2024
- Listed onKRX: 373110
- Listed entityXcell Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINKR7373110006
- Share price1,081.00 KRW (+4.14% on the day) · 2026-10-14
- Market capitalisation17,951,582,474.00 KRW
- EPS (diluted, trailing year)-762.04 KRW
- Volume (last session)63,742
Financials of Xcell Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.95B KRW | -10.93B KRW | -9.15B KRW |
| 2024 | 1.93B KRW | -9.54B KRW | -7.68B KRW |
| 2023 | 1.12B KRW | -9.28B KRW | -7.34B KRW |
| 2022 | 1.02B KRW | -8.34B KRW | -6.79B KRW |
| 2021 | 1.97B KRW | -9.04B KRW | -4.69B KRW |
Detailed financial statements for Xcell Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Xcell Therapeutics
The website of Xcell Therapeutics (xcell.co.kr) receives about 4.6K visits a month.
- Monthly visits4.6K
▼ 19.4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xcell Therapeutics
Complete news archive for Xcell Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xcell Therapeutics
Xcell Therapeutics was founded in 2015.
Xcell Therapeutics is headquartered in Seoul, South Korea.
Uri Uiil Lee is the CEO of Xcell Therapeutics, as recorded in our data.
Xcell Therapeutics has 68 employees.
Annual revenue of Xcell Therapeutics is $1.35M as on Dec 31, 2025.
Xcell Therapeutics was founded in 2015 in Seoul, South Korea, within the biotechnology sector focused on regenerative medicine. Proprietary serum-free media, such as CellCor SFD MSCa fully defined optionand CellCor CD MSCa chemically defined variantare produced for cell culture applications. These products support pharmaceutical solutions in regenerative therapies, with operations centered on advancing cell-based treatments.
Xcell Therapeutics offers CellCorâ„¢ and Exosome Isolation Device.
Yes, Xcell Therapeutics is publicly traded on KRX under the ticker symbol 373110.
Xcell Therapeutics operates through Xcell Therapeutics Inc..